Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

REporting recommendations for tumor MARKer prognostic studies (REMARK).

Lisa M McShane1, Douglas G Altman, Willi Sauerbrei

  • 1National Cancer Institute, Biometric Research Branch, Bethesda, MD 20892-7434, USA. Lm5h@nih.gov

Nature Clinical Practice. Urology
|February 17, 2006
PubMed
Summary

Clinical utility of tumor markers in oncology is limited due to inconsistent study results. New reporting guidelines are proposed to improve the transparency and rigor of tumor marker studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population attributable fraction.

BMJ (Clinical research ed.)·2018
Same author

Reporting guidelines for oncology research: helping to maximise the impact of your research.

British journal of cancer·2018
Same author

Updating standards for reporting diagnostic accuracy: the development of STARD 2015.

Research integrity and peer review·2018
Same author

Do declarative titles affect readers' perceptions of research findings? A randomized trial.

Research integrity and peer review·2018
Same author

Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries.

PloS one·2018
Same author

The INTERGROWTH-21<sup>st</sup> fetal growth standards: toward the global integration of pregnancy and pediatric care.

American journal of obstetrics and gynecology·2018

Area of Science:

  • Oncology
  • Biomarker Research
  • Scientific Reporting

Background:

  • Despite extensive research, few tumor markers have proven clinically useful in oncology.
  • Subsequent studies often yield conflicting or contradictory results for the same tumor markers.
  • Methodological issues and incomplete reporting hinder the assessment of tumor marker study quality and generalizability.

Purpose of the Study:

  • To address the discrepancies in tumor marker study conclusions.
  • To propose guidelines for the transparent and complete reporting of tumor marker studies.
  • To enhance the evaluation of tumor marker data and its clinical applicability.

Main Methods:

  • Review of existing challenges in tumor marker research reporting.
  • Drawing parallels with successful reporting initiatives like CONSORT and STARD.

Related Experiment Videos

  • Development of suggested guidelines for reporting study design, methods, and results.

    • Main Results:

    • Identified a critical need for standardized reporting in tumor marker research.
    • Proposed comprehensive guidelines encompassing study design, patient and specimen details, assay methods, and statistical analysis.
    • Emphasized the importance of data presentation and discussion elements.

    Conclusions:

    • Transparent and complete reporting is crucial for judging the usefulness of tumor marker data.
    • Adherence to proposed guidelines will improve the reliability and interpretability of tumor marker studies.
    • Enhanced reporting will facilitate better understanding of tumor marker utility in clinical oncology.